
IntraGel Therapeutics developed SRGel, a solvent-free, lipophilic long-acting injectable platform that forms a stable, low-pain subcutaneous depot capable of releasing small molecules, peptides, and biologics over weeks to months. The company focuses on converting existing therapeutics into more durable, better-tolerated, and patient-centric LAI products that overcome the injection-site reactions, viscosity limitations, and device burdens associated with current depot technologies.
Annual Revenue$1M to $5M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.